© 2026 Sinochem Nanjing Corporation,
All Right Reserved
As someone who has worked in chemical research labs and pharmaceutical procurement, it's clear that nalidixic acid stands out as an early, synthetic antibiotic under the quinolone group. Developed in the 1960s, nalidixic acid became widely used in the treatment of urinary tract infections. Its proven effectiveness and clear, measurable properties have kept it in circulation, although newer fluoroquinolones now see more applications. This compound comes with its own quirks: you encounter it in several physical forms, including colorless or pale yellow crystals, flakes, powders, and sometimes as a solid amorphous material. Short supply chains, especially for pharmaceutical-grade nalidixic acid, demand a closer look at quality and source. The experience in handling both technical- and pharma-grade nalidixic acid in bulk tells me that attention to sourcing, purity, and regulatory compliance carries tangible benefits for both manufacturers and end-users.
Nalidixic acid has a molecular formula of C12H12N2O3. The molecular weight sits at about 232.24 g/mol. Its crystalline solid state means you see it as powder or pellets, showing off colors from pale yellow to nearly white. The melting point often ranges near 225°C, which requires reliable temperature control in production and transportation settings. The density falls near 1.48 g/cm3. Poor solubility in water but higher solubility in alcohols and acetone defines approaches to formulation and application. Such information doesn’t just live in a data sheet. I’ve seen operators underestimating solvent compatibility, ending up with poor yields or hard-to-mix solutions, all because of these solubility mismatches.
Nalidixic acid carries a quinoline core, with carboxylic acid and ketone functional groups attached at precise locations—a fact that comes through clearly in analytical chemistry and quality testing. Each batch synthesized or procured needs careful structural confirmation: crystallography, NMR, and IR spectra confirm quality. Raw materials include cyclohexanone derivatives and nitro compounds, needing careful handling due to potential hazardous properties. Seeing poorly qualified materials slip through the supply chain highlights the risk of contamination and problems in downstream pharmaceutical production. This chemical structure doesn't just inform its biological effect but anchors quality control steps, both in bulk manufacturing and the development of generics.
In the world of global trade, the Harmonized System Code (HS Code) for nalidixic acid is 2933.49.This number follows the product from factories in India and China through customs across Europe, North America, and many other regions. All experienced buyers check specifications for each shipment: assay percentage should stay above 98% for pharmaceutical batches, limits for heavy metals, chloride content, and moisture percentage must track closely to internationally recognized standards, as outlined by the United States Pharmacopeia or European Pharmacopoeia. Trying to cut corners or work with suppliers ignoring these specs results in expensive regulatory setbacks. These lessons have cost teams millions in recalls and retesting over the years. Consistency in density, purity, and crystal form is part of what gives the final formulation both safety and efficacy, especially in the critical phase of drug manufacturing.
Nalidixic acid comes to labs and plants mainly as powder, but suppliers also offer flakes, pearls, and, less commonly, as pre-mixed solutions in alcohol or water for testing. Over the years, working with these forms taught me that improper handling—letting powder get damp, mixing crystals with the wrong solvents, or failing to store properly—means real risks, from hazardous dust to product degradation. Volume measurements usually fall in the liter range for solutions, while raw orders for the acid itself arrive by kilogram or metric ton. Every step, from weighing out precise grams to preparing solutions for analytical testing, depends on understanding specific density and solubility. Factory floors with poor measuring protocols lose money to spillage and contamination, showing just how practical chemical handling can get.
Nalidixic acid isn’t a benign chemical. Labels clearly mark it as hazardous, both to handlers and the environment. Inhalation, ingestion, or contact with skin calls for immediate first aid: there’s every reason to use face masks, gloves, and proper ventilation. GHS labeling sets its hazard classification. Safety data sheets highlight harmful effects, including eye irritation, cytotoxic effects, and potentially long-term damage with chronic exposure. Anyone working in bulk chemical handling sees the direct cost of lax safety protocols—missed workdays, injuries, or even worse. Waste disposal also follows strict chemical guidelines, with authorities pressing down on companies that discharge residues without proper neutralization. These aren’t abstract risks; years in the chemical industry means witnessing how oversight can lead to regulatory fines and lasting harm.
Global demand remains steady, with nalidixic acid serving as a raw material for both finished antibiotics and intermediate products. Research-grade nalidixic acid supports studies on bacterial DNA replication, while pharmaceutical manufacturing still leans on its proven structure for generic medicines in some regions. In my experience, ongoing research demands close attention to purity and source—academic labs and regulated manufacturers both turn down shipments without full paperwork and certificates of analysis. Market fluctuations and tightening safety rules mean buyers dig deep into supplier records, favoring companies with transparent chemical sourcing and step-by-step batch tracking.
Improving standards in nalidixic acid production and handling starts with transparent sourcing and batch certification. Bringing in more comprehensive spectroscopic and chromatographic testing at every production stage gets ahead of recalls and regulatory issues. Using digital batch records, accessible by both sellers and buyers, shuts down a lot of confusion in trade and reduces the risk of counterfeit material. On the safety side, widespread employee training and strict enforcement of PPE use in factories and warehouses cuts down on injury rates and keeps insurance costs in check. Closing the gap between production, QC, and logistics builds real value for companies and keeps users and the public safer from the hazards of raw chemical material exposure.
